Sweden's Karo Snaps Up LEO's OTC Derma Brands

Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.

MergerAcquisition
• Source: Shutterstock

Sweden’s Karo Pharma AB is poised to beef up its consumer health portfolio by acquiring a basket of brands from Denmark’s Leo Pharma AS for €90m ($101m). The transaction is expected to close during the first quarter of 2020, subject to regulatory approval.

Karo said the acquisition would strengthen its position in Europe, notably in the DACH region (Germany, Austria and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

Australia’s Wellnex Life Poised To Enter UK’s CHC Market

 
• By 

Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.

That Loud Noise Echoing In US OTC Hearing Aid Market? Merger Of Eargo And HearX

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By 

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

More from Business

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

PharmaSGP Targets More Of The Same As It Outperforms OTC Market

 
• By 

Germany-based firm grew three-times faster than the OTC pharmacy market in 2024 and is hoping to continue this momentum in 2025.